Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Nanobody directed towards the human A1 domain of von Willebrand factor

EU orphan designation number: EU/3/09/629   
Active ingredient: Nanobody directed towards the human A1 domain of von Willebrand factor
Indication: Treatment of thrombotic thrombocytopenic purpura
Sponsor: Ablynx N.V.
Technologiepark 21, 9052 Zwijnaarde, België

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/05/2009 Orphan designation EMEA/OD/109/08 (2009)3525 of 30/04/2009
17/08/2010 Change of name and/or address of sponsor EMA/409031/2010